Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study

被引:32
作者
Hayashi, T
Yokota, N
Takahashi, T
Tawara, Y
Nishikawa, T
Yano, T
Furutani, M
Fujikawa, T
Horiguchi, J
Yamawaki, S
机构
[1] HIROSHIMA UNIV,SCH MED,DEPT PSYCHIAT & NEUROSCI,MINAMI KU,HIROSHIMA 734,JAPAN
[2] HIROSHIMA SEIYOIN HOSP,HIROSHIMA,JAPAN
[3] SEIWAKAI NISHIKAWA HOSP,HAMADA,JAPAN
关键词
antidepressants; mianserin; negative symptoms; schizophrenia; serotonin; tardive dyskinesia; trazodone;
D O I
10.1097/00004850-199707000-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the present study was to evaluate the efficacy of mianserin and trazodone as antidepressants with serotonin 2 antagonist properties on negative symptoms and tardive dyskinesia in elderly patients with chronic schizophrenia. In this double-blind, placebo-controlled study the dose of each drug was increased gradually, from 20 mg/day mianserin to 60 mg/day, and from 50 mg/day trazodone to 200 mg/day. Symptoms were assessed using the Brief Psychiatric Rating Scale, the Scale for Assessment of Negative Symptoms and the Abnormal Involuntary Movement Scale every week for 5 weeks. A total of 38 patients (23 men and 15 women) completed the trial. Mianserin (n = 13) and trazodone (n = 12) did not alter the Brief Psychiatric Rating Scale positive symptom factor over the 5 weeks. In the mianserin group, the Scale for Assessment of Negative Symptoms total score decreased significantly after 5 weeks. Scores of 'affective flattening and blunting' and 'alogia' scores on the Scale for Assessment of Negative Symptoms decreased significantly in both treatment groups. In the trazodone group, the decrease in the Abnormal Involuntary Movement Scale total score was statistically significant at weeks 2 and 3. Results indicate that serotonergic antidepressants, when used in conjunction with neuroleptics, are safe and effective for treating negative symptoms in elderly patients with chronic schizophrenia. Results also indicated a possible beneficial effect of trazodone in treating tardive dyskinesia.
引用
收藏
页码:199 / 205
页数:7
相关论文
共 55 条
[41]   THYMOSTHENIC EFFECTS OF RITANSERIN (R-55667), A CENTRALLY ACTING SEROTONIN-S2 RECEPTOR BLOCKER [J].
REYNTJENS, A ;
GELDERS, YG ;
HOPPENBROUWERS, MLJA ;
VANDENBUSSCHE, G .
DRUG DEVELOPMENT RESEARCH, 1986, 8 (1-4) :205-211
[42]  
RICHELSON E, 1982, J CLIN PSYCHIAT, V43, P4
[43]  
SALZMAN C, 1987, J CLIN PSYCHIAT, V48, P19
[44]   THE RELATIONSHIP OF SEROTONIN METABOLISM AND MELATONIN SECRETION TO THE PATHO-PHYSIOLOGY OF TARDIVE-DYSKINESIA [J].
SANDYK, R ;
FISHER, H .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1989, 48 (1-2) :133-136
[45]   CONTRIBUTION OF SEROTONIN NEUROTOXINS TO UNDERSTANDING PSYCHIATRIC-DISORDERS - THE ROLE OF 5-HT2 RECEPTORS IN SCHIZOPHRENIA AND ANTIPSYCHOTIC ACTIVITY [J].
SCHMIDT, CJ ;
KEHNE, JH ;
CARR, AA ;
FADAYEL, GM ;
HUMPHREYS, TM ;
KETTLER, HJ ;
MCCLOSKEY, TC ;
PADICH, RA ;
TAYLOR, VL ;
SORENSEN, SM .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 8 :25-32
[46]  
SNOW BJ, 1992, MOVEMENT DISORDERS N, P230
[47]   EFFECT OF TRAZODONE ON BRAIN DOPAMINE METABOLISM [J].
STEFANINI, E ;
FADDA, F ;
PORCEDDU, ML ;
GESSA, GL .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1976, 28 (12) :925-927
[48]  
SUNDERLAND T, 1987, ARCH GEN PSYCHIAT, V44, P418
[49]  
SUNDERLAND T, 1992, CLIN GERIATRIC PSYCH, P45
[50]  
TUNE LE, 1991, PSYCHIAT CLIN N AM, V14, P353